Assignee
SPARK THERAPEUTICS INC
US·7 granted patents·33 pending applications·0 citations·filing 2016–2025
Top patents by PatentIndex Score
40 records- 0177US2025305024A1Relative potency assay for viral vector encoding isomerohydrolasesSPARK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0275US2025171521A1CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0372US2022387560A1Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0466US2024101972A1Methods of regulating adeno-associated virus productionSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0566US2025073353A1Factor viii (fviii) gene therapy methodsSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0666US2025101396A1Codon-optimized acid alpha-glucosidase expression cassettes and methods of using sameSPARK THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0762US2019038724A1Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 0861US11168124B2CpG reduced factor VIII variants, compositions and methods and uses for treatment of hemostasis disordersSPARK THERAPEUTICS INC·Filed 2017·Granted Nov 9, 2021·0 cites·41 claims
- 0961US2026078097A1Piperazine compoundsSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1059US2024271159A1Aav vector column purification methodsSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1158US12359239B2Relative potency assay for viral vector encoding isomerohydrolasesSPARK THERAPEUTICS INC·Filed 2017·Granted Jul 15, 2025·0 cites·50 claims
- 1258US2024350667A1Method of Enhancing Gene Therapy by Targeting cGAS-STING PathwaySPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1358US2025302990A1Enhancing non-viral dna delivery and expressionSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1457US2025228928A1Immune enhancement and infectious disease treatmentSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1556US12290574B2Optimized promoter sequences, intron-free expression constructs and methods of useSPARK THERAPEUTICS INC·Filed 2019·Granted May 6, 2025·0 cites·35 claims
- 1656US12084693B2Codon-optimized acid alpha-glucosidase expression cassettes and methods of using sameSPARK THERAPEUTICS INC·Filed 2019·Granted Sep 10, 2024·0 cites·40 claims
- 1756US2025221932A1Immune enhancement of cancer treatmentSPARK THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1855US2024074986A1Methods of Enhancing Non-Viral Gene TherapySPARK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1955US2016346359A1Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular DiseaseSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2050US2023040275A1Secretable protein induced immune tolerization and treatment of autoimmune, allergic and other diseases and disordersSPARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2150US2021371877A1Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of useSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2250US2024110201A1Compositions and Methods for Treating Hereditary AngioedemaSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2348US2022025396A1Plasmid free aav vector producing cell linesSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2447US2022184188A1Aav vector treatment methods for late infantile neuronal ceroid lipofuscinosis type 2SPARK THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2546US2025387510A1Adeno-associated virus formulationsSPARK THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2646US2021079422A1Aav vector column purification methodsSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2746US2020164008A1Apheresis methods and usesSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2846US2024301380A1Compositions and Methods for Treating Fabry DiseaseSPARK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2945US2018312571A1CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERSSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3045US2022011308A1In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodiesSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3145US2020237930A1Factor viii (fviii) gene therapy methodsSPARK THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3243US12404526B2Enhancing agents for improved cell transfection and/or rAAV vector productionSPARK THERAPEUTICS INC·Filed 2018·Granted Sep 2, 2025·0 cites·37 claims
- 3343US10633689B2Rab Escort Protein potency assaySPARK THERAPEUTICS INC·Filed 2017·Granted Apr 28, 2020·0 cites·32 claims
- 3443US2019192693A1Methods and vectors for treating cns disordersSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3542US11702639B2Column-based fully scalable rAAV manufacturing processSPARK THERAPEUTICS INC·Filed 2017·Granted Jul 18, 2023·0 cites·47 claims
- 3642US2019284576A1SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBYSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3741US2019292561A1Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical useSPARK THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3839US2021363192A1Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using sameSPARK THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3938US2019078099A1Cell line for recombinant protein and/or viral vector productionSPARK THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4032US2023241247A1Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulinsSPARK THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SPARK THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →